{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:40:08Z","timestamp":1794379208684,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006704","name":"Ostravsk\u00e1 Univerzita v Ostrav\u011b","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["SGS19\/LF\/2023"],"award-info":[{"award-number":["SGS19\/LF\/2023"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106298","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:10:09Z","timestamp":1737709809000},"page":"106298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Analysis of serum natalizumab concentrations obtained during routine clinical care in patients with multiple sclerosis: A cross-sectional study"],"prefix":"10.1016","volume":"94","author":[{"given":"D.","family":"Moskorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-754X","authenticated-orcid":false,"given":"I.","family":"Kacirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hradilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Matlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Brozmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kusnierova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Licha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sistik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Koristkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2025.106298_bib0002","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"10.1016\/j.msard.2025.106298_bib0020","article-title":"No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score\u2013matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)","volume":"14","author":"Butzkueven","year":"2021","journal-title":"Ther. Adv. Neurol. Disor."},{"issue":"14","key":"10.1016\/j.msard.2025.106298_bib0038","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2025.106298_bib0021","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2025.106298_bib0022","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of Natalizumab dosing: is efficacy preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106298_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0011","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","article-title":"\u03b14-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.msard.2025.106298_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1079\/BJN19910073","article-title":"Body mass index as a measure of body fatness: age- and sex-specific prediction formulas","volume":"65","author":"Deurenberg","year":"1991","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.msard.2025.106298_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106298_bib0036","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomized, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106298_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105796","article-title":"Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration","volume":"90","author":"Gelissen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0007","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1212\/NXI.0000000000000591","article-title":"Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS","volume":"6","author":"Ghezzi","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.msard.2025.106298_bib0047","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.msard.2025.106298_bib0051","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13256-024-04562-8","article-title":"Long-lasting severe anemia following treatment with natalizumab for relapsing-remitting multiple sclerosis: a case report","volume":"18","author":"Hamnvik","year":"2024","journal-title":"J. Med. Case Rep."},{"issue":"2","key":"10.1016\/j.msard.2025.106298_bib0048","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200094","article-title":"Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis","volume":"10","author":"Hauser","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106298_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/JCNSD.S14049","article-title":"Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis","volume":"6","author":"Hoepner","year":"2014","journal-title":"J. Cent. Nerv. Syst. Dis"},{"key":"10.1016\/j.msard.2025.106298_bib0005","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3389\/fneur.2018.01071","article-title":"Real-world lab data in natalizumab-treated multiple sclerosis patients up to 6 years long-term follow up","volume":"9","author":"Kaufmann","year":"2018","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0013","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106298_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106298_bib0049","article-title":"Serum teriflunomide concentrations in routine multiple sclerosis therapy: a cross-sectional pilot study","volume":"458","author":"Krska Kusnirikova","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106298_bib0050","article-title":"Natalizumab-induced hyporegenerative anaemia and leukopenia: a case report","volume":"56","author":"Mansoor","year":"2020","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.msard.2025.106298_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115542","article-title":"Liquid chromatography-tandem mass spectrometry method for determination of natalizumab in serum and cerebrospinal fluid of patients with multiple sclerosis","volume":"234","author":"Matlak","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"11","key":"10.1016\/j.msard.2025.106298_bib0053","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/1352458512442262","article-title":"Severe haematological complications during treatment with natalizumab","volume":"18","author":"Midaglia","year":"2012","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2025.106298_bib0010","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106298_bib0043","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jneuroim.2011.11.009","article-title":"Neutrophils in multiple sclerosis are characterized by a primed phenotype","volume":"242","author":"Naegele","year":"2012","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2025.106298_bib0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"A new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"Natalizumab","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0042","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/brainsci14050423","article-title":"The role of neutrophils in multiple sclerosis and ischemic stroke","volume":"14","author":"Nowaczewska-Kuchta","year":"2024","journal-title":"Brain Sci"},{"issue":"3","key":"10.1016\/j.msard.2025.106298_bib0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1352458510385508","article-title":"Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months","volume":"17","author":"Oliver","year":"2011","journal-title":"Mult. Scler. J"},{"key":"10.1016\/j.msard.2025.106298_bib0006","article-title":"Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience","volume":"14","author":"Perncezky","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"issue":"10","key":"10.1016\/j.msard.2025.106298_bib0008","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"15","key":"10.1016\/j.msard.2025.106298_bib0012","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000004485","article-title":"Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients","volume":"89","author":"Plavina","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2025.106298_bib0041","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106298_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614715","article-title":"Does extended interval dosing Natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study","volume":"12","author":"Riancho","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2025.106298_bib0027","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000321072","article-title":"Analysis of past and present methods of measuring and estimating body surface area and the resulting evaluation of its doubtful suitability to universal application","volume":"30","author":"Ruggieri","year":"2010","journal-title":"Blood. Purif."},{"issue":"15","key":"10.1016\/j.msard.2025.106298_bib0037","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2025.106298_bib0046","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.3390\/jcm9113542","article-title":"Inhibition of human neutrophil functions in vitro by multiple sclerosis disease-modifying therapies","volume":"9","author":"Scutera","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106298_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285615615257","article-title":"Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis","volume":"9","author":"Sellebjerg","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106298_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.716548","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses","volume":"12","author":"Serra L\u00f3pez-Matencio","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.msard.2025.106298_bib0052","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1212\/WNL.0000000000000614","article-title":"Severe anemia in a patient with multiple sclerosis treated with natalizumab","volume":"83","author":"Simone","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106298_bib0009","unstructured":"Summary of Product Characteristics: Tysabri\u00ae. European Medicines Agency. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf. Accessed 22 Oct, 2024.10."},{"issue":"12","key":"10.1016\/j.msard.2025.106298_bib0015","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1177\/1352458518813657","article-title":"Therapeutic drug monitoring of natalizumab","volume":"25","author":"Tanaka","year":"2019","journal-title":"Mult Scler J"},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0016","first-page":"392","article-title":"Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)","volume":"95","author":"Toorop","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2025.106298_bib0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/13524585231225855","article-title":"Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis","volume":"30","author":"Toorop","year":"2024","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.msard.2025.106298_bib0032","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106298_bib0014","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2025.106298_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.msard.2025.106298_bib0003","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/1352458512460604","article-title":"Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis","volume":"19","author":"Vennegoor","year":"2013","journal-title":"Mult. Scler. J"},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0034","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40120-024-00647-0","article-title":"Patient preference for subcutaneous versus intravenous administration with every-6-week natalizumab (Tysabri\u00ae) dosing: NOVA phase IIIb extension study (part 2)","volume":"13","author":"Wiendl","year":"2024","journal-title":"Neurol. Ther"},{"key":"10.1016\/j.msard.2025.106298_bib0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"5","key":"10.1016\/j.msard.2025.106298_bib0031","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/jpm11050335","article-title":"Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis","volume":"11","author":"Zarzuelo Romero","year":"2021","journal-title":"J. Pers. Med."},{"issue":"8","key":"10.1016\/j.msard.2025.106298_bib0017","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T14:17:00Z","timestamp":1740665820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":53,"alternative-id":["S2211034825000422"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106298","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of serum natalizumab concentrations obtained during routine clinical care in patients with multiple sclerosis: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106298"}}